Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections
The approval marks a major milestone in the global fight against antimicrobial resistance
The approval marks a major milestone in the global fight against antimicrobial resistance
Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
Crucially, Lupin is the exclusive first-to-file applicant for this product and is eligible for 180-day generic drug exclusivity in the U.S. market
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The syrup launched by company's Chezgreen division is designed to provide supportive care in managing common menstrual concerns such as amenorrhea, dysmenorrhea, and menorrhagia
Subscribe To Our Newsletter & Stay Updated